Draft, not yet released. In stewardship review. Not indexed until the first approved release.

The 2027 agenda

Eight bounded questions open the 2027 synthetic biology agenda. Each comes from a baseline finding, names the initiative that will carry it and the first output due in the 2027 synthetic biology edition.

5 min read0 figures6 tables4 notesNR-XTECH-SYNBIO-GLOBAL-2026-BASELINE

Contents
  1. ·Edition home
  2. ·Executive summary
  3. 1Synthetic biology is a build capability and a governance test
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Design capability outpaces screening and oversight
  8. 6Readings from the other desks
  9. 7The 2027 agenda
    1. 7.1 Questions for the operational series
    2. 7.2 Portfolio proposed for the Q1 2027 alignment
    3. 7.3 The pathway
    4. 7.4 Universe 2027: evidence pack for the synthetic biology candidate mission
    5. 7.5 Handoffs and routing
    6. 7.6 Feeds and signal register
  10. 8Systems in depth
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

7.1Questions for the operational series

  1. Q-01

    How well do synthesis providers screen orders, and how do practices differ by country?

    INI-XT04-SCR-01 · screening coverage; first output: screening practice register.

  2. Q-02

    What do fermentation and cell-free manufacturing need in energy, water and feedstock at commercial scale?

    INI-XT04-ENE-02 · manufacturing footprint; first output: footprint estimates by process.

  3. Q-03

    Which DNA synthesis, instrument and reagent steps are single points of failure?

    INI-XT04-SUP-03 · DNA supply chain; first output: dependence map.

  4. Q-04

    How much biofoundry and bioindustrial capacity exists, and where?

    INI-XT04-CAP-04 · manufacturing capacity; first output: capacity table.

  5. Q-05

    How can public and private investment in synthetic biology be counted on one basis?

    INI-XT04-FIN-05 · investment on a common basis; first output: investment table.

  6. Q-06

    Which national frameworks set screening or oversight rules, and how do they differ?

    To be admitted in 2027; first output: framework overlay.

  7. Q-07

    What workforce exists for design, biofoundry operation and biosafety oversight?

    To be admitted in 2027; first output: scoping note.

  8. Q-08

    Which readiness capabilities have been tested in real incidents, and which are only planned?

    Readiness capability register; first output: rung evidence for 15 functions.

7.2Portfolio proposed for the Q1 2027 alignment

Five initiatives and one Universe mission candidate are proposed for the 2027 synthetic biology portfolio. They are programme objects: no partner, funder or member is attached to them in this edition.

Table 7.1Objects proposed for the first operational quarter
IDObjectKindQuestionState
INI-XT04-SCR-01Screening coverageInitiativeQ-01PROPOSED
INI-XT04-ENE-02Manufacturing footprintInitiativeQ-02PROPOSED
INI-XT04-SUP-03DNA supply chainInitiativeQ-03PROPOSED
INI-XT04-CAP-04Manufacturing capacityInitiativeQ-04PROPOSED
INI-XT04-FIN-05Investment on a common basisInitiativeQ-05PROPOSED
MSN-XT04-2027-01Design and screening Universe missionMissionQ-01Candidate

7.3The pathway

The synthetic biology edition reads national readiness chapters, the coupled sector reports on health, food and biosecurity, and the global edition through one governed evidence graph. At baseline the federation is designed; the global energy, health and food editions are drafted. This page states what exists today and what comes next.

  1. 01

    National readiness chapters

    biotechnology and biosecurity readiness in each national edition

    IN PREPARATION · national baselines

  2. 02

    Sector couplings

    GS-03 food · GS-04 health · XT-05 genomics · SR-08 biosecurity

    GS-04 DRAFTED · sector baselines

  3. 03

    Technology system model

    platforms, DNA supply, manufacturing, workforce, governance

    v0 SPECIFIED · v1 with federation evidence

  4. 04

    Strategic links

    SR-08 health security · SR-13 strategic technology

    PLANNED · strategic baselines

  5. 05

    Universe

    annual proving environment

    CANDIDATE MISSION · mandate in 2027

  6. 06

    XT-04 report

    this series

    BASELINE DRAFT · 2027 annual edition

  7. 07

    Evidence and correction

    one graph, many projections

    OPEN · first correction cycle in 2027

7.4Universe 2027: evidence pack for the synthetic biology candidate mission

  1. 01

    Mandate

  2. 02

    Core Build · 1 month

  3. 03

    Action · 1 week

  4. 04

    Evidence seal

  5. 05

    Portfolio correction

  6. 06

    Next mandate

Table 7.2Universe 2027: evidence pack for the synthetic biology candidate mission
ItemRecordStateTiming
F1Annual mandate recordPLANNEDafter the Q2 2027 alignment
F2Core Build recordPLANNEDone month before the exercise
F3Exercise evidencePLANNEDduring the Action week
F4Decision packetsPLANNEDexercise state only
F5Proof receiptsPLANNEDscoped to each recorded check
F6After-action reportPLANNEDwithin one quarter
F7Upgrade docketPLANNEDrouted to the Portfolio
F8Portfolio renewalPLANNED2027 global annual edition
F9Public synthesisPLANNEDpublic-safe extracts only

Mission

ID
MSN-XT04-2027-01 · Design and screening Universe mission
Role spine
Leadership sponsor · Institutional anchor · Mission lead: drawn from national pathways
Receiving actors
to be identified with the mandate

7.5Handoffs and routing

Where the baseline’s findings go next. A handoff routes a finding for awareness, review or work; it transfers no authority.

Table 7.3Handoffs and routing
FindingRouted toPurposeClass
BLD-001 · recoded genomesINI-XT04-CAP-04manufacturing capacityPUBLIC
CLN-004 · engineered therapiesINI-XT04-FIN-05investment on a common basisPUBLIC
SEC-005 · screening gapsINI-XT04-SCR-01screening coveragePUBLIC
GOV-007 · US frameworkregional consortiaframework overlayPUBLIC
GOV-009 · EU proposalregional consortiaframework overlayPUBLIC
GOV-010 · OECD and CBDINI-XT04-SUP-03DNA supply chainPUBLIC
FIN-011 · company filingsINI-XT04-ENE-02 · key F reviewmanufacturing footprintPUBLIC
SYS-012 · compound pathwayMSN-XT04-2027-01Universe candidateCONSORTIUM
Table 7.4Routing rules by publication class
ClassWhere it goesWho can see it
PUBLICthe published edition and its evidence bundleanyone
CONSORTIUMgoverned rooms of the federationconsortium members under agreement
CONTROLLEDneed-to-know channelsnamed competent actors only

7.6Feeds and signal register

Table 7.5Feeds watched from 2027
FeedProducerLatencyFeeds into
Journals and preprint servers on genome writing and designpeer review and preprintscontinuousBLD-001
Regulator announcements on engineered therapiesUS Food and Drug Administrationper eventCLN-004
Screening and dual-use policy pagesagencies and industry consortiaper releaseSEC-005
EU Biotech Act pagesEuropean Commissionper releaseGOV-009
OECD science and technology policy papersOECDper releaseGOV-010
Company earnings releasesTwist Bioscience, Ginkgo BioworksquarterlyFIN-011
CBD synthetic biology pageCBD secretariatper meetingGOV-010

Escalation routes

  • none · keep monitoring
  • research question
  • project
  • risk object
  • annual publication
  • signal report
Table 7.6Signals at baseline
IDSignalCorroborationSystemsRoute
SIG-XT04-001A 57-codon genetic code was reported in 20251CORROBORATEDBLDresearch question Q-05
SIG-XT04-002Screening tools missed redesigned sequences in a 2025 study13PARTIALSEC · DATresearch question Q-01
SIG-XT04-003No public replacement for the US framework was found2627PARTIALGOVresearch question Q-06

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  2. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  3. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
  4. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 7: The 2027 agenda. In Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

ReportsContribute

Send evidence or a correction on Synthetic Biology and Bioengineering.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology

Never send personal data, sensitive infrastructure detail or anything you have no right to share. A contribution is reviewed before use; sending it confers no authorship or editorial rights, and sponsorship never buys a finding.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

The Global Centre for Risk and Innovation

Science · evidence · measurement

Not for profit

Our articles, maps and twins are free to read and free to republish. Readers and partners keep it that way.

Partner with us

Who funds us

GCRI is a not-for-profit institution. To ask who funds a piece of work, use the funding questions form.

Independence

Editors and the expert reviewers named on each article decide what we publish. Funders and partners do not review or approve articles before publication.

Corrections policy

Licence

Articles: CC BY 4.0. Figures, maps, twins and data: CC BY 4.0. Other uses: ask through the permissions form.

Privacy choices